Comprehensive Study Notes on Mental Health, Depression, Bipolar Disorder, Anxiety, and Sleep Disorders

Quality Use of Medicines (QUM) and Interaction Screening Frameworks

  • National Medicines Policy & QUM Core Goal:

    • Medicines management is a shared responsibility across the multidisciplinary healthcare team to optimize individual patient outcomes.

    • Quality Use of Medicines (QUM) mandates selecting management options judiciously, choosing appropriate medicines when necessary, using them safely, and ensuring maximum therapeutic efficacy.

  • The MESS Framework for Screening Drug-Drug Interactions:

    • M – Mechanism: Identify whether the interaction is pharmacokinetic (PK) (e.g., altered absorption, distribution, metabolism via cytochrome P450 enzymes, or renal excretion) or pharmacodynamic (PD) (e.g., additive or antagonistic physiological effects at receptor sites).

    • E – Evidence: Determine the literature and clinical evidence supporting the interaction using validated clinical decision support tools (e.g., Australian Medicines Handbook [AMH], eMIMSelite, AusDI).

    • S – Severity: Assess the potential clinical impact and harm level (ranging from mild adverse effect to life-threatening toxicity or multi-organ failure).

    • S – Symptoms/Monitoring: Define specific clinical signs and laboratory parameters to monitor, and establish an actionable management plan.

Major Depressive Disorder (MDD)

  • Diagnostic Criteria and Key Clinical Features:

    • Characterized by persistent depressed mood and/or loss of interest or pleasure in almost all activities (anhedonia) lasting for at least 2 weeks2\,\text{weeks}, accompanied by significant functional impairment.

    • Core Clinical Symptoms:

    • Sleep disturbance (insomnia or hypersomnia).

    • Appetite or weight changes.

    • Impaired concentration, indecisiveness, or poor cognitive focus.

    • Persistent fatigue or loss of energy.

    • Feelings of worthlessness or excessive/inappropriate guilt.

    • Recurrent thoughts of death or suicidal ideation.

  • Pathophysiology and Rationale for Antidepressant Therapy:

    • Multifactorial Etiology: MDD arises from a complex interaction of genetic susceptibility, biological factors, psychological vulnerability, and environmental stressors.

    • Altered Neurotransmission: Grounded in the monoamine hypothesis, MDD involves dysregulation of central neurotransmitters, specifically serotonin (5-HT5\text{-HT}), noradrenaline (NA\text{NA}), and dopamine (DA\text{DA}).

    • Neuroendocrine Dysregulation: Persistent hyperactivity or dysfunction of the Hypothalamic-Pituitary-Adrenal (HPA\text{HPA}) axis leads to elevated cortisol levels and blunted feedback loops.

    • Impaired Neuroplasticity: Reduced brain-derived neurotrophic factor (BDNF\text{BDNF}) expression leads to impaired synaptic plasticity and structural alterations in brain regions regulating mood, cognition, and behavior (such as the hippocampus and prefrontal cortex).

    • Pharmacotherapeutic Rationale: Antidepressant medications aim to restore synaptic monoamine concentrations, downregulate post-synaptic receptors, normalize HPA-axis function, and stimulate neuroplastic processes over time.

Bipolar Disorder (BD) and Mood Stabilizers

  • Clinical Features of Bipolar Disorder:

    • Characterized by recurrent episodes of mania or hypomania alternating with depressive episodes.

    • Key Features of Mania:

    • Abnormally elevated, expansive, or irritable mood.

    • Significantly decreased need for sleep without fatigue.

    • Increased goal-directed activity or psychomotor agitation.

    • Grandiosity or inflated self-esteem.

    • High-risk, impulsive behaviors (e.g., reckless spending, foolish business investments, sexual indiscretions).

  • Rationale for Management:

    • Broad management goals prioritize mood stabilization across acute manic/depressive phases, long-term relapse prevention, and reduction of overall suicide risk.

  • Lithium Pharmacotherapy and Quality Use of Medicines (QUM):

    • High-risk classification reasons:

    • Narrow Therapeutic Index: Tiny margin between therapeutic serum levels and toxic thresholds.

    • Exclusively Renal Elimination: Clearance is entirely dependent on glomerular filtration rate (GFR\text{GFR}) and renal perfusion.

    • High Toxicity Risk: Mild elevations cause gastrointestinal distress and fine tremor; severe elevations cause confusion, ataxia, seizures, arrhythmias, and multi-organ failure.

    • Extensive Drug Interactions: Highly sensitive to alterations in fluid/electrolyte balance and co-administered drugs.

    • Monitoring Demands: Mandatory routine serum drug concentration monitoring.

    • Critical Drug Interactions:

    • NSAIDs (e.g., ibuprofen): Reduce renal prostaglandin synthesis →\rightarrow decreased renal perfusion →\rightarrow reduced lithium clearance →\rightarrow increased serum lithium concentrations →\rightarrow high risk of severe toxicity.

    • Fluoxetine: Co-administration increases the risk of serotonin toxicity and neurotoxicity.

    • Special Population Considerations:

    • Pregnancy:

      • Classified as TGA Prescribing Category D. Avoid during the first trimester if possible due to cardiovascular malformation risks (e.g., Ebstein anomaly).

      • Renal clearance of lithium increases significantly during the second half of pregnancy, requiring potential dose increases.

      • Serum lithium monitoring schedule: Check levels monthly, increase to weekly from 36 weeks36\,\text{weeks} gestation, and reassess within 24 hours24\,\text{hours} post-delivery.

      • Use reliable pregnancy references such as the Pregnancy and Breastfeeding Medicines Guide (PBMG).              

        Pregnancy and Breastfeeding Medicines Guide
    • Older Adults:

      • Age-related decline in renal function decreases lithium clearance, escalating toxicity risks.

      • Requires lower initial dosing ("start low, go slow").

      • Requires closer monitoring of serum lithium concentrations, renal function, and electrolytes.

    • Patient Counselling and Practice Points:

    • Administer doses with food to minimize gastrointestinal upset.

    • Do not crush, chew, or cut sustained-release (SR) formulations, and avoid taking SR formulations with hot drinks.

    • Educate patients on maintaining stable fluid and sodium intake.

    • Counsel patients to recognize early toxicity symptoms (coarse tremor, vomiting, diarrhea, unsteadiness).

Generalised Anxiety Disorder (GAD) and Sleep Disorders

  • Clinical Features of GAD:

    • Characterized by excessive, uncontrollable anxiety and worry regarding multiple events or activities, occurring most days for at least 6 months6\,\text{months}.

    • Manifests with symptoms such as restlessness, feeling keyed up or on edge, easy fatigability, poor concentration, muscle tension, irritability, and sleep disturbance.

  • Management Principles for GAD:

    • First-Line Non-Pharmacological: Cognitive Behavioral Therapy (CBT) accompanied by ongoing psychosocial support for all patients.

    • Indications for Pharmacotherapy: Indicated when symptoms are severe, psychotherapy is unavailable, or CBT alone has proven ineffective.

    • First-Line Pharmacotherapy: Selective Serotonin Reuptake Inhibitors (SSRIs). Patients must be counselled that therapeutic effects require 2–4 weeks2\text{--}4\,\text{weeks} to emerge.

    • Benzodiazepines: Restricted strictly to short-term, acute symptom management due to high risks of tolerance, physiological dependence, and cognitive impairment.

Case Analysis: Serotonergic Toxidrome & Medication Management

  • Case Profile (James, 29-Year-Old Male):

    • High-stress corporate environment (Sydney law firm).

    • Initial self-management: St John's Wort (Hypericum perforatum) 1 capsule BD1\,\text{capsule BD} (naturopath recommendation).

    • Prescribed medication history:

    • Fluoxetine 20 mg nocte20\,\text{mg nocte} (prescribed by GP; minimal improvement at 2 weeks, exacerbated insomnia).

    • Venlafaxine 75 mg nocte75\,\text{mg nocte} (commenced 1 week ago as a direct switch from fluoxetine without counselling or a washout period).

    • Tramadol 100 mg BD100\,\text{mg BD} (prescribed for chronic pain).

    • Salbutamol 100 μg 1–4 puffs PRN100\,\mu\text{g 1--4 puffs PRN} and 10 minutes prior to exercise.

    • Acute Emergency Presentation:

    • High fever, uncontrollable tremors, palpitations, agitation, rapid speech, poor focus.

    • Vital signs: Blood pressure 172/104 mmHg172/104\,\text{mmHg}, Heart rate 112 bpm112\,\text{bpm}, Temperature 39.8∘C39.8^\circ\text{C}.

  • Pathophysiology of Serotonergic Toxidrome (Serotonin Toxicity):

    • Severe, life-threatening clinical state resulting from overstimulation of central and peripheral serotonin receptors (5-HT1A5\text{-HT}_{1A} and 5-HT2A5\text{-HT}_{2A}) due to cumulative serotonergic drug load.

    • eTG Clinical Diagnostic Triad:

    • Neuromuscular Excitation: Hyperreflexia, inducible or spontaneous clonus, ocular clonus, myoclonus, shivering, tremor, hypertonia, rigidity.

    • Autonomic Dysfunction: Moderate-to-high pyrexia/hyperthermia (temperature >39∘C> 39^\circ\text{C} or rapidly rising), sweating/diaphoresis, flushing, mydriasis, tachycardia, unstable blood pressure.

    • Central Nervous System (CNS) Effects: Agitation, anxiety, confusion, altered conscious state (delirium is typically not prominent).      

      Serotonergic toxidrome guidelines from eTG
  • Medication-Related Problems (MRPs/DRPs) Identified:

    • Concomitant Serotonergic Polypharmacy: Dangerous combination of St John's Wort, fluoxetine, venlafaxine, and tramadol.

    • Inadequate Washout Period: Fluoxetine has an exceptionally long elimination half-life (t1/2t_{1/2}) due to its active metabolite norfluoxetine. Australian Medicines Handbook (AMH) guidelines require a minimum 14-day14\text{-day} drug-free washout period when switching from fluoxetine to another SSRI, SNRI, or TCA (and up to 5 weeks5\,\text{weeks} depending on individual washout characteristics).

    • Sub-Optimal Dosing Schedule: Administering fluoxetine at bedtime (nocte) directly worsens insomnia; activating antidepressants must be taken in the morning (mane).

    • Premature Therapy Switch: Switching therapy after only 2 weeks is inappropriate; an antidepressant trial requires at least 4 weeks4\,\text{weeks} at a therapeutic dose to evaluate full clinical response.

    • Inappropriate Opioid Regimen: Chronic tramadol therapy for non-cancer pain carries significant risks of tolerance, dependency, and serotonergic interaction.

    • Inappropriate Inhaler Administration: PRN salbutamol dosing (1–4 puffs1\text{--}4\,\text{puffs}) requires review regarding proper spacer usage and alignment with updated guidelines (2026 Australian Asthma Handbook).

  • Optimized Quality Use of Medicines (QUM) Action Plan:

    • Cease non-prescription St John's Wort immediately.

    • Deprescribe tramadol by tapering and substituting non-opioid analgesics (e.g., regular paracetamol, NSAIDs, or COX-2 inhibitors) to achieve an opioid-sparing effect.

    • Maintain a single, appropriately dosed antidepressant (e.g., fluoxetine administered in the morning) for a full 4-week4\text{-week} trial before assessing efficacy or considering dosage adjustments.

    • Reinforce non-pharmacological support: Exercise, sleep hygiene, alcohol avoidance, cognitive behavioral therapy/counselling.

    • Multidisciplinary Team Integration: Engage GP, pharmacist, psychologist (counselling), physiotherapist (pain origin management), and clinic nurse.

    • PBS Brand Options: Search via the Pharmaceutical Benefits Scheme (PBS) website demonstrates that 10 commercial brands of fluoxetine and 7 commercial brands of venlafaxine are available in Australia.

  

PBS Search interface
  • Standardized Terminology and Governance:

    • Clinical documentation must adhere to national guidelines published by the Australian Commission on Safety and Quality in Health Care regarding safe medicine terms, abbreviations, and dose designations.

  

Recommendations for safe use of medicines terminology

Pharmacotherapeutic Reference Profile

  • Escitalopram:

    • Therapeutic Class: Selective Serotonin Reuptake Inhibitor (SSRI).

    • Prefix/Suffix: -pram.

    • Mechanism of Action: Potent, selective inhibition of presynaptic serotonin (5-HT5\text{-HT}) reuptake transporters, enhancing synaptic serotonin concentration in the CNS.

    • Therapeutic Indications: Major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder.

    • Important Side Effects / Practice Points: Nausea, diarrhoea, insomnia, somnolence, sexual dysfunction, dose-dependent QT prolongation, risk of serotonin toxicity, withdrawal syndrome upon abrupt discontinuation.

  • Venlafaxine:

    • Therapeutic Class: Serotonin and Noradrenaline Reuptake Inhibitor (SNRI).

    • Prefix/Suffix: -faxine.

    • Mechanism of Action: Potent inhibitor of presynaptic serotonin (5-HT5\text{-HT}) and noradrenaline (NA\text{NA}) reuptake; weak inhibitor of dopamine reuptake at high therapeutic doses.

    • Therapeutic Indications: Major depressive disorder, generalized anxiety disorder, social anxiety disorder, panic disorder.

    • Important Side Effects / Practice Points: Dose-dependent hypertension, tachycardia, sweating, nausea, dizziness, severe discontinuation syndrome (requires gradual dose tapering over weeks).

  • Amitriptyline:

    • Therapeutic Class: Tricyclic Antidepressant (TCA).

    • Prefix/Suffix: -triptyline.

    • Mechanism of Action: Non-selective inhibitor of serotonin (5-HT5\text{-HT}) and noradrenaline (NA\text{NA}) reuptake; additionally blocks histaminergic (H1\text{H}_1), muscarinic cholinergic, and α1\alpha_1--adrenergic receptors, and cardiac fast sodium channels.

    • Therapeutic Indications: Major depressive disorder, neuropathic pain, migraine prophylaxis.

    • Important Side Effects / Practice Points: Anticholinergic toxicity (dry mouth, urinary retention, constipation, blurred vision), prominent sedation, orthostatic hypotension, weight gain, high risk of lethal cardiac arrhythmias in overdose.

  • Mirtazapine:

    • Therapeutic Class: Noradrenergic and Specific Serotonergic Antidepressant (NaSSA).

    • Prefix/Suffix: -zapine.

    • Mechanism of Action: Antagonizes central presynaptic α2\alpha_2--adrenergic autoreceptors and heteroreceptors (enhancing NA\text{NA} and 5-HT5\text{-HT} release); selectively blocks 5-HT25\text{-HT}_2 and 5-HT35\text{-HT}_3 receptors and histamine H1\text{H}_1 receptors.

    • Therapeutic Indications: Major depressive disorder (particularly beneficial in patients with accompanying severe insomnia or appetite/weight loss).

    • Important Side Effects / Practice Points: Marked sedation (dosing at bedtime recommended), increased appetite, weight gain, low incidence of sexual dysfunction, rare risk of blood dyscrasias/agranulocytosis.

  • Lithium:

    • Therapeutic Class: Mood Stabilizer.

    • Prefix/Suffix: N/A.

    • Mechanism of Action: Alters neuronal sodium cation transport; inhibits inositol monophosphatase, depleting intracellular second messengers (IP3 and DAG); downregulates glutamate neurotransmission and enhances GABA\text{GABA} function.

    • Therapeutic Indications: Bipolar disorder (treatment of acute mania, maintenance therapy, relapse prevention), treatment-resistant depression augmentation.

    • Important Side Effects / Practice Points: Fine hand tremor, polyuria, polydipsia, nephrogenic diabetes insipidus, hypothyroidism, renal impairment, gastrointestinal distress, weight gain, narrow therapeutic range requires regular serum level checks.

  • Diazepam:

    • Therapeutic Class: Benzodiazepine.

    • Prefix/Suffix: -azepam.

    • Mechanism of Action: Binds allosterically to the GABAA\text{GABA}_A receptor sub-type, enhancing the affinity of gamma-aminobutyric acid (GABA\text{GABA}) and increasing chloride channel opening frequency, causing hyperpolarization and neuronal inhibition.

    • Therapeutic Indications: Short-term management of severe anxiety, acute muscle spasm, alcohol withdrawal syndrome, acute status epilepticus, conscious sedation.

    • Important Side Effects / Practice Points: Sedation, drowsiness, motor ataxia, cognitive dysfunction, anterograde amnesia, respiratory depression; high potential for psychological/physical dependence and tolerance (use restricted to short durations of <2–4 weeks< 2\text{--}4\,\text{weeks}).